|
|
|
|
true
10000
-
10 Years of science and counterterrorism
Dr. Robert Liddington solved the crystal structure of the anthrax lethal factor. Later, he and several colleagues discovered chemical inhibitors that neutralize the anthrax lethal factor, making a significant advance toward a treatment.
-
Robert Liddington lives where structure meets function
The National Institute of General Medical Sciences at the NIH awarded a five-year, $6.8 million grant to a team led by Dr. Robert Liddington. With this funding, the researchers will study protein complexes that mediate cell adhesion.
|
|
Studying infectious diseases
Researchers in the Infectious Diseases Program seek to better understand the molecular mechanisms of disease. One area of research focuses on structure-function correlates of virulence factors and essential genes from bacteria and viruses, including the processing proteases of the flaviviruses (e.g. West Nile and Dengue virus) and variola virus, the causative agent of smallpox. Building on this infrastructure, the program is also studying emerging diseases including potential pandemic viruses. Achievements by researchers in this program have included a significant advance toward an emergency treatment for anthrax.
|
|
The need to understand and develop treatments for infectious diseases is great. It is currently estimated that within the next 10 years many antibiotics currently employed for treating bacterial infections will no longer be effective due to microbial resistance. Drug-resistant strains of some pathogens, such as the bacteria that cause tuberculosis, have already appeared. In addition, very few treatments for viral infections exist to date. Moreover, several deadly viral agents are on the rise.
How our research helps improve health
With continued exploration of how viral and bacterial infections attack the body and spread, researchers can develop vaccines and treatments for diseases. These could be crucial when the next pandemic illness strikes, and can improve the quality of life for those living will illnesses such as HIV.
Research - Infectious and Inflammatory Disease - Infectious
Disease: How Our Research Helps |
|
|
-
Selective and potent furin inhibitors protect cells from anthrax without significant toxicity.
Remacle AG, Gawlik K, Golubkov VS, Cadwell GW, Liddington RC, Cieplak P, Millis SZ, Desjardins R, Routhier S, Yuan XW, Neugebauer WA, Day R, Strongin AY.
Int J Biochem Cell Biol. 2010 Jun;42(6):987-95. Epub 2010 Mar 1.
Read More
-
Genetics: Rare genes for autoimmunity-the new kids on the block.
Satterthwaite AB, Mohan C.
Nat Rev Rheumatol. 2010 Dec;6(12):678-9.
Read More
-
High-throughput screen for the chemical inhibitors of antiapoptotic bcl-2 family proteins by multiplex flow cytometry.
Curpan RF, Simons PC, Zhai D, Young SM, Carter MB, Bologa CG, Oprea TI, Satterthwait AC, Reed JC, Edwards BS, Sklar LA.
Assay Drug Dev Technol. 2011 Oct;9(5):465-74. Epub 2011 May 11.
Read More
-
Mechanism of Bcl-2 and Bcl-X(L) inhibition of NLRP1 inflammasome: loop domain-dependent suppression of ATP binding and oligomerization.
Faustin B, Chen Y, Zhai D, Le Negrate G, Lartigue L, Satterthwait A, Reed JC.
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3935-40. Epub 2009 Feb 17.
Read More
-
Intradomain cleavage of inhibitory prodomain is essential to protumorigenic function of membrane type-1 matrix metalloproteinase (MT1-MMP) in vivo.
Golubkov VS, Chernov AV, Strongin AY.
J Biol Chem. 2011 Sep 30;286(39):34215-23. Epub 2011 Aug 8.
Read More
-
The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation.
Steinberg MW, Cheung TC, Ware CF.
Immunol Rev. 2011 Nov;244(1):169-87. doi: 10.1111/j.1600-065X.2011.01064.x.
Read More
View All Publications
Research - Infectious and Inflammatory Disease - Infectious
Disease: Recent Publications |
|
Global - Left Nav: Bottom Blue Border
|
|
|
|
|
|